Drug Delivery Support

Drug delivery support services and expertise in targeted drug delivery development

Targeted drug delivery involves innovative methods to transport pharmaceutical substances within the body, ensuring therapeutic effects are achieved with precision. Recent advancements in drug delivery technologies and drug delivery devices in the sector have focused on administering drugs at the optimal time, dosage, and location, maximizing safety and efficacy.

These technologies are gaining attention for their ability to enhance the effectiveness of both new and existing drugs through targeted, controlled, and sustained delivery. Drug delivery technology includes controlled release systems, targeted drug delivery mechanisms, and smart technologies that respond to specific stimuli such as pH or temperature. Innovations like nanoparticle drug delivery are enabling precise targeting of diseases such as cancer, while sustained-release drug delivery formulations help maintain therapeutic drug levels over extended periods.

As new therapies and reformulations of traditional molecules are developed, the need for advanced drug delivery product development to optimize their potential benefits is critical. Our scientists are committed to supporting innovators focused on drug development and delivery of new drug candidates to targeted tissues and cells. We have supported global innovators in drug delivery methods across multiple modalities, helping them target previously undruggable sites and gain a deeper understanding of controlled drug release systems for patient-friendly formulations.

Our 30 years of experience in the development of complex dosage forms, backed by GLP/GCP/GMP standards, propels our partners’ programs forward daily. With specialist expertise in orally inhaled and intranasal drug delivery (OINDPs) and oral drug delivery, we offer integrated analytical testing, formulation, and clinical manufacturing capabilities to support a wide range of projects. Our expertise spans both small molecules and biologics with dedicated facilities for their characterization. We assist in selecting the right delivery platforms and device technologies tailored to your needs.

We have also supported the development of novel drug delivery systems that promote cellular uptake, including such as liposome drug delivery, lipid nanoparticles, nanoparticle drug delivery, polymer-based systems and ligand conjugation approaches through characterization and quality control testing across multiple product classes such as proteins, monoclonal antibodies, ADCs, DNA medicines, mRNA, gene therapies and vaccines. Our scientists provide analytical methodologies to assess critical quality attributes essential for development and regulatory submissions, and we can conduct extractables and leachables studies through our extensive network of laboratories and consultants.

Our scientists provide analytical methodologies to assess critical quality attributes essential for development and regulatory submissions, and we can conduct extractables and leachables studies through our extensive network of laboratories and consultants.

Inhalation Drug Product Analysis

OINDP Product Performance Analysis
IVBE Studies
Clinical & Finished Product Release Testing
Extractables/Leachables
MDRS Particle Studies

Formulation Development

Product Development & Characterisation

Device Compatibility Studies
Device Verification Testing
Patient In-use / Misuse Studies

GMP Stability Studies

ICH & Bespoke Conditions
Outsourcing Stability
Temperature Cycling
Photostability Studies
Contingency Storage

In Vitro Performance Testing

In Vitro Performance Testing

In Vitro Bioequivalence (IVBE) Studies
Comparator Studies
Dissolution Testing
Realistic Flow Profiles

Device Experience

Device Experience

Pressurized Metered Dose Inhalers (pMDI)
Nasal Sprays
Dry Powder Inhalers (DPI)
Nebulizers, Soft Mist OINDPs

OINDP Particle and Powder Characterisation 100

Powder and Particle Morphology Studies

MDRS Particle Size Studies
Powder and Particle Characterisation
Laser Particle and Droplet Sizing
Sub-visible Particle Determination

Inhaled and Nasal Biologic Drug Development

Strengths in both biologic characterisation (ICH Q6B) and assessment of the delivered dose uniformity from device and particle size of the emitted drug

Oligonucleotide Characterisation

Confirm your oligonucleotide therapies identity, determine safety, efficacy, purity, quality, and strength and identify and quantify contaminants

COVID-19 mRNA Drug Development Characterisation

mRNA Characterisation and Analysis

Supporting mRNA therapeutic and vaccine development to assess clinical translation efficiency and immunogenicity. Brochure: mRNA Characterisation Services